ArQule Gets a New CEO
Wade Roush4/15/08
Woburn, MA-based ArQule, which is developing several compounds known as kinase inhibitors as potential cancer therapies, said today that Paolo Pucci, a Bayer senior vice president overseeing Bayer-Schering’s global oncology and therapeutics business, will take over as the company’s new CEO. Pucci succeeds Stephen Hill, a nine-year veteran of the company who announced his approaching departure in January and left ArQule to become president and CEO of Brussels, Belgium-based Solvay Pharmaceuticals on April 1.
Wade Roush is Xconomy's chief correspondent and editor of Xconomy San Francisco. You can e-mail him at wroush@xconomy.com or follow him on Twitter at twitter.com/wroush.
